Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants With HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer

Next Previous
Trial Profile

An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants With HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenti HPV 07 (Primary)
  • Indications Cervical cancer; Human papillomavirus infections; Oropharyngeal cancer
  • Focus Adverse reactions
  • Sponsors THERAVECTYS

Most Recent Events

  • 04 Oct 2024 According to THERAVECTYS media release, preliminary results on safety and immunogenicity are expected in a couple of months, after all patients in one group will have received their last injection.
  • 04 Oct 2024 According to THERAVECTYS media release, first patient has been enrolled in this trial. The selection and inclusion of these patients are already underway. The dose-escalation protocol will include 36 patients at several cancer centers in USA.
  • 04 Oct 2024 According to THERAVECTYS media release, status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top